Sionna Therapeutics SION 深 沪
等待开盘 10-01 09:30:00 美东时间
5.26
+0.110
+2.14%
华盛通- 最 高5.3421
- 今 开5.19
- 成交量 115.75万股
- 最 低 5.02
- 昨 收 5.15
- 总市值 2.38亿
- 52周最高 54.97
- 市盈率 静 --
- 换手率 2.56%
- 52周最低 4.01
- 委 比 -82.19%
- 总股本 4521.24万
- 历史最高 54.97
- 量 比 0.98
- 振 幅 6.25%
- 历史最低 4.01
- 每 手 1
- 风险率 12.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Sionna Therapeutics Restructures to Focus on Dual Combination
Sionna Therapeutics, Inc. ( ($SION) ) has provided an update. On September 9, 2...
09-15 04:30
Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving measures...
09-15 04:03
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Sionna Therapeutics announced plans to advance its dual combination therapy SION-451 + SION-2222 into a Phase 2a proof-of-concept trial for cystic fibrosis (CF), following post hoc analysis of the PreciSION CF trial. The analysis revealed that SION-719 demonstrated biological activity, but confounding factors such as PK outliers and drug interactions may have affected results. The new trial is expected to begin in Q1 2027. The company also implem...
09-14 20:01
美股牛股 | 云计算概念狂飙！NEBIUS飙升34%，CoreWeave升超19%；QNT劲升28%
云计算概念狂飙！NEBIUS飙升34%，AI云收入暴增514%；CoreWeave升超19%，积压订单破千亿美元；QNT劲升28%，携手甲骨文布局量子云+财报指引超预期>>
08-13 16:27
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Guggenheim Downgrades Sionna Therapeutics to Neutral
Guggenheim analyst Yatin Suneja downgrades Sionna Therapeutics (NASDAQ:SION) from Buy to Neutral.
08-11 22:17
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
周一，福泰制药(VRTX.US)早盘涨近7%，创历史新高;而竞争对手Sionna Therapeutics(SION.US)暴跌超90%，创记录新低。消息面上...
08-10 23:39
Sionna Reports Mixed Trial Results, Refocuses CF Pipeline
Sionna Therapeutics, Inc. ( ($SION) ) has shared an announcement. On August 10,...
08-10 19:48
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
